



برسك الشدالرحمن بسكم المثد الرحمن



سورة طه

الأية ﴿ ١١٤﴾

Postpartum rectal Misoprostol in addition to intraoperative IV Oxytocin Vs Intra-operative IV Oxytocin alone to reduce intra-operative & postoperative blood loss

Thesis Submitted for partial fulfillment of Master Degree (M.sc) in Obstetrics and Gynecology.

Ву

Sally Alaa El-Dien Ibrahim Mohamed El-Attar

(M.B., B.Ch., Cairo University).

Supervised by:

PROF. Ehab Mohamed Soliman

Professor of Obstetrics and Gynecology Department

Faculty of Medicine-Cairo University

Dr. Abdalla Yehia El Kateb

Assistant professor of Obstetrics and Gynecology

Faculty of Medicine-Cairo University

Dr. Heba Wageih Saeid

Lecturer of Obstetrics and Gynecology

Faculty of Medicine-Cairo University

2015

ميزوبروستول الشرجى بعد الولادة القيصرية بالإضافة إلى الأوكسيتوسين الوريدى أثناء العملية مقابل الأوكسيتوسين الوريدى أثناء العملية فقط فى تقليل فقد الدم أثناء وبعد العملية

رسالة مقدمة من

الطبيبة/ سالى علاء الدين إبراهيم محمد العطار

بكالوريوس الطب والجراحة، كلية طب قصر العيني

توطئة للحصول على درجة الماجيستير

فی

التوليد وأمراض النساء

تحت إشراف

أ.د.إيهاب محمد سليمان

أستاذ التوليد وأمراض النساء

كلية الطب - جامعة القاهرة

د.عبد الله يحيى الكاتب

أستاذ مساعد التوليد وأمراض النساء

كلية الطب - جامعة القاهرة

د.هبة وجيه سعيد

مدرس التوليد و أمراض النساء

كلية الطب - جامعة القاهرة

Acknowledgment

First of all I thank **God** for all his blessings throughout my life. I thank my **family** for their continuous support through all the hard and difficult times.

I would like to express my deepest gratitude and appreciation to **Prof Ehab Soliman**, professor of Obstetrics and Gynecology, Faculty of Medicine, Cairo University, for his continuous guidance and precious encouragement. I feel great honor to work under his supervision.

I am also greatly indebted to **Dr Abdallah Al Kateb**, Assistant Professor of Obstetrics & Gynaecology, Faculty of Medicine, Cairo University for his faithful help, sincere guidance and constant support that facilitated the completion of this work.

I would also like to thank **Dr. Heba Wageih,** lecturer of Obstetrics & Gynaecology, Faculty of Medicine, Cairo University for her continuous support and encouragement that helped me a lot to finish this work.

Finally, I would like to thank my patients without whom this work would not have been possible.

Index

		Page
•	List of tables, figures & abbreviations	I
•	Abstract	V
•	Introduction	1
•	Aim of work	3
•	Review of literature	4
	 Management of 3rd stage of labor Oxytocin Misoprostol Cesarean section 	34 39
•	Patients & Methods	50
•	Results	53
•	Discussion	62
•	Conclusion & Recommendations	66
•	Summary	67
•	References	69
•	Arabic Summary	

LIST OF TABLES

Number	Title	Page
Table 1	Comparison of Active Management of Third Stage of Labor versus expectant (physiologic) management	7
Table 2	Predisposing factors and causes of immediate postpartum hemorrhage	11
Table 3	Degrees of hypovolemia and shock	16
Table 4	Algorithm for management of atonic postpartum hemorrhage	17
Table 5	The demographic data; maternal age, gestational age and parity among the studied groups	53
Table 6	Comparison between the two groups regarding need for additional uterotonic agents	55
Table 7	Comparison between the two groups regarding estimated mean operative blood loss	56
Table 8	Comparison between the two groups regarding change in haemoglobin	57
Table 9	Comparison between the two groups regarding change in hematocrit	58
Table 10	Comparison between preoperative and postoperative Mean arterial blood pressure and pulse among the two groups	59
Table 11	Comparison between the two groups regarding need for blood transfusion	61

LIST OF FIGURES

Number	Title	Page
Figure 1	Brandt-Andrews maneuver for cord traction	8
Figure 2	Technique of bimanual massage for uterine atony	15
Figure 3	the SOS Bakri tamponade balloon	20
Figure 4	Summary of application of B-Lynch	22
Figure 5	The influence of oxytocin on myometrial cells	35
Figure 6	maternal age, gestational age and parity and among the two groups	54
Figure 7	A pie chart presenting the distribution of patients in group 1 regarding the number of previous CS	54
Figure 8	A pie chart presenting the distribution of patients in group 2 regarding the number of previous CS	55
Figure 9	Need for uterotonic agents among the two groups	56
Figure 10	Estimated mean operative blood loss among the two groups	57
Figure 11	Change in hemoglobin among the two groups	58
Figure 12	Change in hematocrit among the two groups	59
Figure 13	Comparison between pre-operative and post- operative mean arterial pressure among the two groups	60
Figure 14	Comparison between pre-operative and post- operative pulse among the two groups	60
Figure 15	Need for blood transfusion among the two groups	61

ABBREVIATIONS

ACOG American College of Obstetricians and Gynecologists

AFE Amniotic fluid embolism

AMTSL Active Management of Third Stage of Labor

APH AntePartum Hemorrhage

 $AUC0-\infty$ Antibiotics Area under the concentration time-curves from time zero to infinity

BP Blood pressure

CCT Controlled Cord Traction

Cmax maximum Concentration

CS Cesarean Section

CTG Cardiotocography

DAG Diacylglycerol

DIC Disseminated Intravascular Coagulopathy

DVT/PE Deep Vein Thrombosis/Pulmonary Embolism

ED90 The dose of a therapeutic agent that eradicates 90% of the target pathogen

FDA Food and Drug Administration

FFP Fresh Frozen Plasma

HCV Hepatitis C Virus

HELLP Hemolysis, Elevated Liver enzymes, Low Platelets

HIV Human Immunodeficiency Virus

HPLC High performance liquid chromatography

IM Intramuscular

IP3 inositol tri-phosphate

ITP Idiopathic Thrombocytopenic Purpura

IUD Intrauterine death

List of tables, figures & abbreviations

IV Intravenous

MAP Mean arterial pressure

mg Milligram

mL milliliter

NO Nitric Oxide

NSAIDs Non Steroidal Anti-Inflammatory Drugs

PET Preeclampsia Toxaemia

PGE1 Prostaglandins E1

PGE2 Prostaglandins E2

PGF2 α Prostaglandins F2 α

PPH Postpartum Hemorrhage

RCOG Royal College of Obstetricians and Gynecologists

RIA Radioimmunoassay

SAE Selective Arterial Embolization

SOGC Society of Obstetricians and Gynecologists of Canada

SROM Spontaneous Rupture Of Membranes

TOP Termination of pregnancy

UI Urinary incontinence

UK United Kingdom

USA United States of America

VBAC Vaginal Birth After Cesarean

vWD von Wilebrand's Disease

WCC White Cell Count

WHO World Health Organization

Objective: The current study is designed to compare the efficacy of post-partum rectal misoprostol in addition to intra-operative IV oxytocin to intra-operative IV oxytocin alone during cesarean delivery to reduce intra-operative and post-operative blood loss.

Study design: This is an interventional prospective controlled study assessing the use of postpartum rectal misoprostol in addition to intraoperative IV oxytocin during cesarean delivery to reduce intra-operative and postoperative blood loss in comparison with routinely used intra operative intravenous oxytocin injection alone. The Study is composed of 150 women undergoing elective or emergency cesarean delivery under general or spinal anaesthesia, subjects included in the study will be randomized into 2 groups:

- •First group (75 women): will receive post-partum misoprostol 800 ug, administered rectally in addition to intra-operative 5 IU of IV Oxytocin.
- •Second group (75 women): will receive intra-operative 5 IU of Oxytocin after the delivery of the neonate as slow IV dose.

Results: In our study, differences in the age, parity and gestational age were statistically insignificant among the two groups. In our study, 32 % among the first group patients needed further uterotonic agents compared to 26 % of the patients in the other group, also 14.7 % out of the first group needed blood transfusion, compared to 12 % of the second group, which is statistically insignificant. According to our study, no statistical significance was found between IV Oxytocin alone and post-operative rectal misoprostol in addition to Intra-operative IV Oxytocin in the estimated mean operative blood loss, hemoglobin and hematocrit values preoperatively and postoperatively and pulse and mean arterial pressure measured both pre-operatively & post-operatively.

Conclusion: To date Oxytocin is the drug of choice in the management of the third stage of labour.

Keywords: Misoprostol, Oxytocin, postpartum hemorrhage.

Abstract

Postpartum hemorrhage (PPH) is the leading cause of maternal death worldwide, with an estimated mortality rate of 140 000 women per year, or 1 maternal death every 4 minutes (**Leduc et al.,2009**).

PPH occurs in 5% of all deliveries and is responsible for a major part of maternal mortality (**Reynders et al.,2006**).

The majority of these deaths occur within 4 hours of delivery, which indicates that they are a consequence of the third stage of labour (**Ramanathan et al.,2006**). Non fatal PPH results in further interventions, iron deficiency anemia, pituitary infarction (Sheehan's syndrome) with associated poor lactation, exposure to blood products, coagulopathy, and organ damage with associated hypotension and shock (**Leduc et al.,2009**).

Since all parturient women are at risk for PPH, care providers need to possess the knowledge and skills to practice active management of the third stage of labour, to prevent PPH and to recognize, assess, and treat excessive blood loss (**Leduc et al.,2009**). Caesarean section is a recognized risk factor for PPH and the worldwide caesarean delivery rate is increasing (viler et al.,2006).

Systematic reviews have concluded that active management of third stage of labour, particularly the prophylactic use of uterotonic agents can significantly decrease the incidence of postpartum haemorrhage compared with that of expectant management. An ideal uterotonic agent should promote prompt, strong and sustained uterine contractions after intramuscular (IM) injection without any significant adverse effects (**Leung et al.,2006**).

The administration of oxytocics after the delivery of the neonate reduces the likelihood of PPH and 5 IU oxytocin by slow intravenous injection is currently recommended for all caesarean sections(NICE, 2007). However, the use of additional oxytocic medication is common (Wedisinghe et al.,2008), to arrest bleeding, or prophylactically if there are risk factors for PPH.

Carbetocin is a synthetic analogue of human oxytocin with structural modifications that increase its half life thereby prolonging its pharmacological effects. Two double-blind randomised trials compared 100 microgramg carbetocin (the licensed dose) with different combinations of oxytocin, bolus and infusion, following caesarean section. The first trial found that significantly more women needed additional oxytocic interventions in the oxytocin group. The second trial found no significant differences in the intraoperative blood loss (**Leduc et al.,2009**).

Introduction

Misoprostol is a synthetic prostaglandin E1 analogue that has been found to be as effective as dinoprostone and oxytocin in inducing labor and as a uterotonic agent (Elhassan et al.,2007).

Aim of work

- 1- To compare the efficacy of post-partum rectal misoprostol in addition to intraoperative IV oxytocin to intra-operative IV oxytocin alone during cesarean delivery to reduce intra-operative and post-operative blood loss.
- 2- Subsequent need of additional uterotonic drugs.
- 3- To document safety and evaluate adverse events recorded during the study either maternal or fetal.

Chapter 1

Management of third stage of labor

The third stage of labor is the stage of separation and expulsion of the placenta (Cunningham et al., 2010). It is perhaps the most dangerous part of labor for the mother, the main danger is post partum hemorrhage (PPH) (McDonald et al., 1993).

Primary PPH is one of the top five causes of maternal mortality in both developed and developing countries found that the most important risk factors for severe PPH were related to an abnormal third stage of labor. The most common abnormalities being third stage more than or equals 30 minutes and retained placenta (Mousa and Alfirevic, 2007).

A recently published study concluded that a third stage longer than 18 minutes is associated with a significant risk of PPH. After 30 minutes ,the odds of having PPH are 6 times higher than before 30 minutes (**Magann and Lanneau, 2005**).

Several complications encountered in the third stage of labor may lead to maternal morbidity. PPH may cause anemia or lead to poor iron reserves, ultimately contributing to anemia. Anemia may cause weakness and fatigue. Hospitalization may be prolonged, and the establishment of breastfeeding may be affected. A blood transfusion may ameliorate the anemia and shorten the hospital stay, but it carries risks of transfusion reaction and infection. Access to safe blood is not universal, and PPH can sometimes strain the resources of the best blood bank. Severe PPH ,retained placenta, and uterine inversion may require emergency anesthetic services. Any exploration or instrumentation of the uterus increases the risk of sepsis (AbouZahr, 1998).

Expectant Versus Active Management

The controversy surrounding third-stage management exists between authorities who advocate the physiological or expectant approach and those who advocate the active approach. The basic components of the two management strategies are outlined in table (1).

• Expectant management